Presentations & Publications

VRON-0200, a Therapeutic HBV Vaccine With an Intrinsic Checkpoint Inhibitor, Elicits Broad CD8+ T Cell Responses and Sustained Antiviral Declines in Preclinical Studies


Hasanpourghadi M, et al.

Oral –

EASL, Abstract #OS-2478

Dr. Hildegund Ertl, Professor in the Vaccine & Immunotherapy Center at The Wistar Institute and the Scientific Founder of Virion Therapeutics, LLC, presented data on VRON-0200 chronic hepatitis B virus (HBV) program at the European Association for the Study of the Liver (EASL) – International Liver Congress (ILC) 2021. [12:30 mins]

This oral presented was identified for inclusion in Best of ILC.